Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38679221/
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically important weight loss effects in patients with type 2 diabetes. However, its effects on sustained weight loss in patients without diabetes...
Semaglutide (2.4 mg) significantly reduces body weight in overweight/obese individuals without diabetes, with a 12.1% relative weight loss. Gastrointestinal adverse events are common but mostly mild. Long-term efficacy and safety are confirmed.
Targeting the GDF15 Signalling for Obesity Treatment: Recent Advances and Emerging Challenges - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39700016/
The growth differentiation factor 15 (GDF15)-glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) pathway plays a crucial role in the regulation of metabolism, appetite and body weight control. Obesity is...
The GDF15-GFRAL pathway regulates metabolism, appetite, and obesity. Targeting this axis offers a promising strategy for obesity treatment, with minimal impact on muscle mass, though challenges remain in its application.
Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38299476/
The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.
This review explores GLP-1 receptor-binding medications for obesity, assessing their mechanisms, efficacy, and safety, highlighting key treatments like retatrutide, tirzepatide, and semaglutide, with an emphasis on long-term outcomes.
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39295512/
The rapid and widespread clinical adoption of highly effective incretin-mimetic drugs (IMDs), particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the updating of clinical practice guidelines. Consequently,...
Incretin-mimetic drugs for obesity may cause muscle loss, impacting health. Adequate protein, micronutrients, and resistance training are essential to preserve muscle mass, optimize therapy, and minimize risks in patients.
Pharmacologic Treatment of Overweight and Obesity in Adults - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/25905267/
Obesity pharmacotherapy has evolved significantly over the past 60 years. Today, six anti-obesity medications (AOMs) are approved by the Federal Drug Administration (FDA) for the long-term treatment of obesity. Similar...
Obesity pharmacotherapy has evolved with six FDA-approved medications for long-term weight management, recommended for individuals with BMI ≥30 or ≥27 with comorbidities, alongside lifestyle modifications for effective treatment.